A recent discovery highlighted by Anthropic demonstrates how artificial intelligence may accelerate the search for entirely new biological tools for genetic engineering.
Anthropic reports that its AI agents identified a previously uncharacterized system called array-associated reverse transcriptases (ARTs) in bacteriophage genomes. The system combines a reverse transcriptase, an adjacent partner gene, and a repeated genetic array with some architectural similarities to CRISPR. Initial laboratory work confirmed that the system is biologically active and produces short RNAs, although its natural function and potential as a gene-editing technology remain to be established.
For SOHM’s ABBIE platform, the discovery is significant because it illustrates the expanding universe of naturally occurring DNA-manipulating systems.
Potential relevance to ABBIE
ABBIE is being explored as a potential nonviral DNA-integration platform based on integrase/recombinase biology. As ABBIE research progresses, AI-assisted genomic analysis could potentially help identify:
● Related or alternative integrases and recombinases
● Accessory proteins that influence DNA integration
● Natural mechanisms affecting integration-site selection
● Enzymes with improved activity or stability
● Components that could improve delivery or integration efficiency
This could be particularly relevant to CAR-T manufacturing, where researchers are seeking efficient and controllable nonviral approaches for introducing therapeutic genetic cargo into T cells.
AI could also help analyze large numbers of ABBIE integration sites and genomic datasets, potentially revealing relationships between integration and DNA sequence, chromatin state, or other genomic features. Experimental validation would then be required to determine whether those observations translate into improved performance or safety.
A broader opportunity
The ART discovery highlights a potentially important trend in biotechnology: AI can help researchers search biological diversity for molecular systems that have previously escaped recognition.
For ABBIE, this creates the possibility of moving beyond optimization of a single system toward a broader DNA-engineering platform incorporating newly identified enzymes, accessory factors and targeting mechanisms.
ABBIE remains in development, and its integration efficiency, integration-site profile, reproducibility and safety characteristics require further experimental validation. However, advances in AI-driven biological discovery could provide SOHM with additional tools and scientific directions as the company evaluates ABBIE for CAR-T cell engineering, gene therapy and other potential biotechnology applications.
The next generation of genome engineering may not come from modifying only the tools we already know—it may come from discovering the biological tools we have not yet found.